ImmuCell Q2 2026 revenue rises 11.5% to $7.2 million; net income $1.8 million
ImmuCell reported unaudited results for the quarter ended June 30, 2026, with product sales up 11.5% to $7.2 million and net income of $1.8 million, or $0.20 per diluted share, versus $0.5 million, or $0.06 per basic share, a year earlier. Gross margin fell to 33.9% from 43.7%, and net income includes a one-time $2 million settlement payment from a former contract manufacturer.
Key points
- Product sales rose 11.5% to approximately $7.2 million in Q2 2026, compared with the quarter ended June 30, 2025.
- Gross margin declined to 33.9% of product sales from 43.7%, which the company attributed to lower manufacturing volumes, scrap from a quality issue with a purchased material, and shifted costs from the discontinued Re-Tain program.
- Adjusted EBITDA was $2.7 million, compared with $1.4 million a year earlier; cash and cash equivalents rose to $8.9 million at June 30, 2026, from $3.8 million at December 31, 2025.
- The company plans a capacity expansion of about $3.5 million (freeze-drying, first phase) and about $4.5 million (colostrum liquid processing, second phase), to be financed with cash on hand and cash from operations.
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.